A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business Overview We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies. Our two commercial products, ARIKAYCE® and BRINSUPRI®, are both part of the Respiratory therapeutic area. ARIKAYCE is approved in the US as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590mg (amikacin sulfate inhalation drug product).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 245M | - |
| Net Income | -1.3B | -1.3B | -914M | -750M | -482M | -435M |
| EPS | $-6.42 | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 |
| Free Cash Flow | -968M | -968M | -706M | -550M | -410M | -371M |
| ROIC | -126.9% | -99.8% | -65.8% | -91.0% | -39.7% | -44.5% |
| Gross Margin | - | - | - | - | 77.5% | - |
| Debt/Equity | 0.74 | 0.74 | 3.89 | -3.50 | 12.82 | 1.38 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -1.2B | -1.2B | -878M | -710M | -457M | -375M |
| Operating Margin | 0.0% | - | - | - | -186.4% | - |
| ROE | -172.8% | -249.3% | -320.2% | - | -547.5% | -105.9% |
| Shares Outstanding | 199M | 199M | 164M | 140M | 123M | 112M |
INSMED Inc passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 77.5%. At current prices, the estimated annualized return to fair value is -26.8%.
INSMED Inc (INSM) has a 5-year average return on invested capital (ROIC) of -68.2%. This is below average and may indicate limited pricing power.
INSMED Inc (INSM) has a market capitalization of $30.5B. It is classified as a large-cap stock.
INSMED Inc (INSM) does not currently pay a regular dividend.
INSMED Inc (INSM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
INSMED Inc (INSM) generated $-968 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
INSMED Inc (INSM) has a debt-to-equity ratio of 0.74. This indicates moderate leverage.
INSMED Inc (INSM) reported earnings per share (EPS) of $-6.42 in its most recent fiscal year.
INSMED Inc (INSM) has a return on equity (ROE) of -249.3%. A negative ROE may indicate losses or negative equity.
INSMED Inc (INSM) has a 5-year average gross margin of 77.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for INSMED Inc (INSM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
INSMED Inc (INSM) has a book value per share of $3.72, based on its most recent annual SEC filing.
No recent press releases.